-+ 0.00%
-+ 0.00%
-+ 0.00%

Asahi Kasei Therapeutics starts Phase 2a trial of AIC468 for BK virus in kidney transplant patients

PUBT·10/08/2026 12:30:49
Listen to the news
Asahi Kasei Therapeutics starts Phase 2a trial of AIC468 for BK virus in kidney transplant patients
  • Asahi Kasei began dosing patients in a randomized Phase 2a trial of AIC468 for BK virus infection in kidney transplant recipients.
  • Early Phase 1 results in healthy volunteers were previously presented, supporting the move into patient testing.
  • The study aims to assess safety and tolerability, positioning AIC468 as a potential targeted option in a setting with no approved therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asahi Kasei Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610080830BIZWIRE_USPR_____20261008_BW761302) on October 08, 2026, and is solely responsible for the information contained therein.